Aventis (NYSE:AVE)
Historical Stock Chart
From Jun 2019 to Jun 2024
Ventiv Health Announces Sales and Marketing Agreement with
Aventis
Contract Calls for Over 450 Sales Representatives Focused on Primary Care and
Specialist Markets
SOMERSET, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Ventiv Health, Inc.
(NASDAQ:VTIV) announced today that it has signed a sales and marketing
agreement with Aventis Pharmaceuticals (NYSE:AVE) that incorporates Ventiv's
broad range of integrated services.
Under the terms of the agreement, Ventiv Health will provide Aventis a
specialized sales force of 452 full-time Sales Representatives, 50 Area
Managers, a National Business Director, two Project Directors, one Project
Manager and one Project Liaison. The scope of the agreement will include sales
force recruitment, training, analysis and reporting, as well as full
operational support of the Aventis/Ventiv sales force. Ventiv will also
provide fulfillment, distribution, and warehousing of samples and literature
through its PROMOTECH division. The Aventis/Ventiv team will target both
primary care and specialty physicians promoting a variety of products
nationwide.
"Today's announcement underscores the many solutions that Ventiv offers the
pharmaceutical industry," said Eran Broshy, CEO of Ventiv Health. "No matter
what their size, all pharmaceutical companies need to flexibly optimize their
resources. Ventiv provides a low risk, cost efficient way to partner with an
experienced outsourced sales and marketing services provider. This agreement
reflects the changing dynamics in the pharmaceutical sales marketplace and
Ventiv is on the forefront of this positive change."
Commenting on the agreement, Terrell Herring, President and COO, Ventiv Pharma
Services(TM) said, "Aventis is an ideal partner for Ventiv Pharma Services
since we are able to work collaboratively with the entire Aventis Sales and
Marketing team to provide a full range of services. Building a premier sales
force for one of the pharmaceutical industry's biggest players is a testament
to Ventiv and the quality of our services. We are pleased with this show of
confidence and look forward to this working relationship."
About Aventis
Aventis is dedicated to treating and preventing disease by discovering and
developing innovative prescription drugs and human vaccines. In 2003, Aventis
generated sales of euro 16.79 billion (US $18.99), invested euro 2.86 billion
(US $3.24) in research and development and employed approximately 69,000 people
in its core business. Aventis corporate headquarters are in Strasbourg, France.
The company's prescription drugs business is conducted in the U.S. by Aventis
Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For
more information, please visit: http://www.aventis-us.com/.
About Ventiv Health
Ventiv Health, Inc. (NASDAQ:VTIV) is a leading provider of sales, marketing,
and compliance solutions to the world's largest pharmaceutical companies as
well as to emerging and specialty pharmaceutical and biotech organizations.
Ventiv has established its leadership position within the industry based on a
long history of building and managing sales teams and providing consultative
planning and analytics services across multiple therapeutic areas.
The Ventiv delivery model is flexible and client focused, enabling Ventiv to
rapidly respond to changing client needs and market conditions across the full
spectrum of sales and marketing support, with both integrated and independent
programs. These include: Sales and Marketing Teams (Ventiv Sales and Marketing
Teams(TM)), Planning and Analytics (Health Products Research(R)), Recruitment
(Ventiv Recruitment Services(TM)), Professional Development and Training
(Ventiv Professional Development Group(TM)), Marketing Support (PROMOTECH),
Data Solutions (Total Data Solutions(TM)), Clinical Support (The Therapeutics
Institute(TM)), and Sample Accountability/Patient Assistance Programs (The
Franklin Group). Ventiv is a multi-discipline company with a singular focus on
providing excellence in customized solutions to meet clients' sales and
marketing objectives.
Ventiv's approximately 2,600 employees support over forty client organizations.
For more information on Ventiv Health, visit http://www.ventiv.com/.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments; and, our ability
to operate successfully in new lines of business. Readers of this press
release are referred to documents filed from time to time by Ventiv Health Inc.
with the Securities and Exchange Commission for further discussion of these and
other factors.
DATASOURCE: Ventiv Health, Inc.
CONTACT: InvestorsCorporate - John Emery, CFO of Ventiv Health, Inc.,
+1-732-537-4804, ; or Media - Felicia Vonella of Lazar
Partners Ltd., +1-212-867-1762,
Web site: http://www.ventiv.com/